Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valrocemide

Drug Profile

Valrocemide

Alternative Names: SPD 493; TV 1901; TVP 1901; Valproyl glycinamide; VGD

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Epilepsy

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Feb 2008 Discontinued - Phase-I for CNS disorders in USA (PO)
  • 09 Mar 2007 Phase-I clinical trials in CNS disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top